DexCom, Inc.

DXCM Healthcare Medical - Devices NASDAQ

PDF Back to Search

$73.24

+$0.38 (+0.52%)

Open: $72.94 | High: $73.59 | Low: $72.65 | Prev Close: $72.86

Market Cap: $28.72B

Volume: 2.4M | Avg: 6.6M

Last updated: January 26, 2026 at 06:02 PM
Featured In

This stock appears in the following dashboards:

Options Activity
Featured
Unusual Options
Featured
Options Screener
Featured
Options Activity for DXCM
Options Screener Data
Type Strike Expiration Premium Premium Yield Call Vol Put Vol P/C Ratio Rating
N/A $N/A N/A $N/A N/A% N/A N/A N/A N/A/10
View Full Options Screener
Puts/Calls Activity
Type Strike Expiration Premium Volume ROI % Breakeven Delta
N/A $N/A N/A $N/A N/A N/A% $N/A N/A
View Full Options Activity
Investment Rating
B

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 3/5
60%
Neutral
ROE Score 5/5
100%
Strong Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 2/5
40%
Sell
P/B Score 1/5
20%
Strong Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 555

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 35
Financial Health 50
Growth 100
Market Sentiment 10
Risk 40
Lower is better
Valuation 20
Momentum 0
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 40.69
P/B Ratio 10.50
P/S Ratio 6.36
EPS $1.80
Beta 1.48
Shares Outstanding 392.16M
Price Range & Moving Averages
52-Week High $93.25
52-Week Low $54.11
SMA 50 $65.82
SMA 200 $73.96
Earnings
Next Earnings February 12, 2026 09:00 PM ET
Financial Ratios
Margins
Gross Margin 59.0%
Operating Margin 17.2%
Net Margin 16.0%
Returns
ROE 29.8%
ROA 9.6%
Liquidity & Leverage
Debt/Equity 0.92
Current Ratio 1.56
Quick Ratio 1.38
Balance Sheet
Total Assets $6.48B
Total Liabilities $4.38B
Total Equity $2.10B
Cash $606.10M
Total Debt $2.59B
Net Debt $1.98B
Income Statement
Revenue $4.03B
Gross Profit $2.44B
Operating Income $600.00M
Net Income $576.20M
EBITDA $945.70M
Revenue/Share $11.55
Cash Flow
Operating CF $989.50M
CapEx $358.80M
Free Cash Flow $630.70M
Book Value/Share $6.97
Tangible Book/Share $6.71
Equity/Share $6.97
Technical Indicators
RSI (14) 50.00 Neutral
MACD
0.00 Signal: 0.00
Volatility 0.00%
Trading Signal Neutral
Performance & Returns

Insufficient historical data

Insufficient historical data (need 200+ days, have 0)
Sector Comparison (Healthcare)
Compared to 45 peers in Healthcare
Metric DXCM Sector Avg Percentile
P/E Ratio 40.69 35.16 71%
P/B Ratio 10.5 0.04 87%
ROE (%) 29.82% 13.83% 72%
Net Margin (%) 15.96% 9.51% 63%
Stock Score 555 466.0 83%
Percentile: 0% = worst in sector, 100% = best in sector
Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
DXCM $73.24 $0.00 $0.00 $0.00 $0.00 $0.00 50.00 0.00 0.00% 0 Neutral Mixed
Candlestick Patterns

There wasn't any recognizable pattern for the DXCM stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
DXCM Strs Ohio Sells 14,796 Shares of DexCom, Inc. $DXCM Neutral defenseworld.net Read More
DXCM Campbell & CO Investment Adviser LLC Has $629,000 Holdings in DexCom, Inc. $DXCM Neutral defenseworld.net Read More
DXCM 1 Growth Stock Down 19% to Buy Right Now Positive fool.com Read More
DXCM DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Neutral defenseworld.net Read More
DXCM DexCom Stock Declines Following Strong Preliminary Q4 Results Negative zacks.com Read More
Recent Insider Trading

No recent insider trading data available for DXCM

Company Information

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CEO Jacob Steven Leach
Employees 10200
Country US
IPO Date 2005-04-14
Exchange NASDAQ
Website https://www.dexcom.com
Sector Healthcare
Industry Medical - Devices
Similar Stocks (Healthcare - Medical - Devices)
ABT

Abbott Laboratories

Price: $108.43
Change: +0.94%
Market Cap: $1887B
P/E: 29.15
Score: E (510)
View Details
BSX

Boston Scientific Corporation

Price: $93.74
Change: +1.33%
Market Cap: $1390B
P/E: 50.13
Score: E (520)
View Details
SYK

Stryker Corporation

Price: $357.20
Change: +0.61%
Market Cap: $1366B
P/E: 47.00
Score: E (520)
View Details
EW

Edwards Lifesciences Corporation

Price: $84.12
Change: +0.56%
Market Cap: $4938B
P/E: 36.89
Score: D (545)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.